Abstract
In a pilot randomized trial comparing a prescription opioid taper support intervention to usual care, lower opioid doses and pain severity ratings were observed at 22weeks in both groups. The groups did not differ significantly at 22weeks in opioid dose or pain severity, but the taper support group improved significantly more in pain interference, pain self-efficacy, and perceived opioid problems. These results support the feasibility and promise of this opioid taper support intervention.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have